131 related articles for article (PubMed ID: 34225450)
21. A new geldanamycin analogue from Streptomyces hygroscopicus.
Zhang H; Sun GZ; Li X; Pan HY; Zhang YS
Molecules; 2010 Mar; 15(3):1161-7. PubMed ID: 20335971
[TBL] [Abstract][Full Text] [Related]
22. A unique macrolactam derivative via a [4+6]-cycloaddition from Streptomyces niveus.
Li L; Cai Y; Jiang Y; Liu J; Ma J; Yuan C; Mu Y; Han L; Huang X
Bioorg Med Chem Lett; 2016 Mar; 26(6):1599-1604. PubMed ID: 26874404
[TBL] [Abstract][Full Text] [Related]
23. Antarlides F-H, new members of the antarlide family produced by Streptomyces sp. BB47.
Saito S; Fujimaki T; Panbangred W; Sawa R; Igarashi Y; Imoto M
J Antibiot (Tokyo); 2017 May; 70(5):595-600. PubMed ID: 28174422
[TBL] [Abstract][Full Text] [Related]
24. Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions.
Suzuki Y; Kondo Y; Hara S; Kimata R; Nishimura T
Int J Urol; 2010 Mar; 17(3):281-5. PubMed ID: 20409220
[TBL] [Abstract][Full Text] [Related]
25. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.
Lamoureux F; Thomas C; Yin MJ; Kuruma H; Fazli L; Gleave ME; Zoubeidi A
Clin Cancer Res; 2011 Apr; 17(8):2301-13. PubMed ID: 21349995
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.
Shafi AA; Cox MB; Weigel NL
Steroids; 2013 Jun; 78(6):548-54. PubMed ID: 23380368
[TBL] [Abstract][Full Text] [Related]
27. DNA Binding and Molecular Dynamic Studies of Polycyclic Tetramate Macrolactams (PTM) with Potential Anticancer Activity Isolated from a Sponge-Associated Streptomyces zhaozhouensis subsp. mycale subsp. nov.
Dhaneesha M; Hasin O; Sivakumar KC; Ravinesh R; Naman CB; Carmeli S; Sajeevan TP
Mar Biotechnol (NY); 2019 Feb; 21(1):124-137. PubMed ID: 30542952
[TBL] [Abstract][Full Text] [Related]
28. Cyclizidine-Type Alkaloids from Streptomyces sp. HNA39.
Jiang YJ; Li JQ; Zhang HJ; Ding WJ; Ma ZJ
J Nat Prod; 2018 Feb; 81(2):394-399. PubMed ID: 29389122
[TBL] [Abstract][Full Text] [Related]
29. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
30. Non-Benzoquinone Geldanamycin Analog, WK-88-1, Induces Apoptosis in Human Breast Cancer Cell Lines.
Zhao YR; Li HM; Zhu M; Li J; Ma T; Huo Q; Hong YS; Wu CZ
J Microbiol Biotechnol; 2018 Apr; 28(4):542-550. PubMed ID: 29618179
[TBL] [Abstract][Full Text] [Related]
31. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
32. Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity.
Onodera H; Kaneko M; Takahashi Y; Uochi Y; Funahashi J; Nakashima T; Soga S; Suzuki M; Ikeda S; Yamashita Y; Rahayu ES; Kanda Y; Ichimura M
Bioorg Med Chem Lett; 2008 Mar; 18(5):1588-91. PubMed ID: 18243703
[TBL] [Abstract][Full Text] [Related]
33. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
[TBL] [Abstract][Full Text] [Related]
34. New geldanamycin analogs from Streptomyces hygroscopicus.
Wu CZ; Jang JH; Ahn JS; Hong YS
J Microbiol Biotechnol; 2012 Nov; 22(11):1478-81. PubMed ID: 23124337
[TBL] [Abstract][Full Text] [Related]
35. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
[TBL] [Abstract][Full Text] [Related]
36. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
[No Abstract] [Full Text] [Related]
37. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
38. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
39. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
40. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]